Global Depression Treatment Market Size study, By Product Type (Drugs, TMS Devices), By Disease (Major Depression, Persistent Depressive Disorder, Seasonal Affective Disorder (SAD), Situational Depression, Treatment-Resistant Depression, Others), and Regi

Global Depression Treatment Market Size study, By Product Type (Drugs, TMS Devices), By Disease (Major Depression, Persistent Depressive Disorder, Seasonal Affective Disorder (SAD), Situational Depression, Treatment-Resistant Depression, Others), and Regional Forecasts 2022-2028

Global Depression Treatment Market is valued at approximately USDXX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2028. Depression is a health condition in which an individual’s mood is elevated or lower which causes a loss of interest and persistent feeling of sadness. Depression treatment includes medication, consulting therapy, or a combination of both. The rising incidences of depression worldwide, the growing need for therapies and antidepressants for curing mental conditions, coupled with increasing healthcare expenditure are the primary factors excelling the global market demand. For instance, according to Statista analysis, in 2020, nearly 2.1 million cases of depression among senior citizens were registered in India. Also, the figure is anticipated to rise and reach around 5 million cases of depression among senior citizens. Accordingly, the rapidly growing cases of depression among the global population are accelerating the demand for depression treatment, which is augmenting the market growth around the world. However, adverse effects of drugs and necessary gaps in treatment impede the growth of the market over the forecast period of 2022-2028. Also, the rising economic burden of mental disorders and the availability of a wide range of treatment options are anticipated to act as catalyzing factors for the market demand during the forecast period.

The key regions considered for the global Depression Treatment Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the rising prevalence of various depression and anxiety disorders, along with the availability of skilled professionals. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the growing population, as well as rising investment in the R&D activities for the development of antidepressant drugs, would create lucrative growth prospects for the Depression Treatment Market across the Asia-Pacific region.

Major market players included in this report are:
Viatris (Mylan Pharmaceuticals Inc.)
Sunovion Pharmaceuticals
AbbVie Inc. (Allergan, Inc.)
Jubilant Generics Limited
Sanis Health Inc.
(Apotex Holdings, Inc.) Apotex Corporation
Alembic Pharmaceuticals Limited
Pfizer Inc.
BrainsWay Ltd.
Nexstim Plc

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product Type:
Drugs
TMS Devices
By Disease:
Major Depression
Persistent Depressive Disorder
Seasonal Affective Disorder (SAD)
Situational Depression
Treatment-Resistant Depression
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Depression Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Viatris (Mylan Pharmaceuticals Inc.)
Sunovion Pharmaceuticals
AbbVie Inc. (Allergan, Inc.)
Jubilant Generics Limited
Sanis Health Inc.
(Apotex Holdings, Inc.) Apotex Corporation
Alembic Pharmaceuticals Limited
Pfizer Inc.
BrainsWay Ltd.
Nexstim Plc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.